Cell News and Research

RSS

Aegera Therapeutics commences AEG35156 Phase 2B study for AML

Aegera Therapeutics Inc. announced today the dosing of the first patient in a randomized Phase 2B study of AEG35156, a targeted antisense therapeutic in mid-stage development for multiple oncology indications.

19 Nov 2009

WaferGen Biosystems launches new SmartChip Service for gene-expression profiling of thousands of genes

WaferGen Biosystems, Inc., a leading developer of state-of-the-art genetic analysis systems, today announced a new, innovative service for gene-expression profiling of thousands of genes using the SmartChip(TM) Real-Time PCR System. By taking advantage of the SmartChip Real-Time PCR system, WaferGen will offer universities, pharmaceutical and diagnostic companies a service that utilizes pathway-specific gene panels to discover and validate new biomarkers.

19 Nov 2009

ISCO, Scripps Research Institute collaborate in study of parthenogenetic stem cells

International Stem Cell Corporation, announced today that it is collaborating with renowned stem cell researcher Jeanne F. Loring, Ph.D., and the Scripps Research Institute (La Jolla, CA) to study parthenogenetic stem cells and potentially therapeutic cells that can be derived from them.

19 Nov 2009

Interim data from Geron's ongoing imetelstat trial presented at the AACR-NCI-EORTC conference

Geron Corporation today announced the presentation of interim data from its ongoing trial of imetelstat (GRN163L), a telomerase inhibitor drug, in patients with refractory, advanced solid cancers at the 2009 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.

19 Nov 2009

Exaggerated responses of immune system explain elders’ susceptibility to viral infections

Researchers at Yale School of Medicine have found that exaggerated responses of the immune system explain why the elderly succumb to viral infections more readily than younger people. Published in the November 19 Cell Host & Microbe, the study bucks the general belief that declining immune responses are to blame for susceptibility to viral infections.

19 Nov 2009

Brain uses a mechanism to filter out distracting thoughts to focus on single information

The human brain is bombarded with all kinds of information, from the memory of last night's delicious dinner to the instructions from your boss at your morning meeting. But how do you "tune in" to just one thought or idea and ignore all the rest of what is going on around you, until it comes time to think of something else?

19 Nov 2009

NanoString Technologies to investigate molecular networks with the Broad Institute of MIT and Harvard

NanoString Technologies, Inc., a privately held life sciences company marketing a molecular barcoding detection system, today announced that it is collaborating with the Broad Institute of MIT and Harvard to investigate molecular networks involved in immune response and other important biological processes.

From NanoString Technologies 19 Nov 2009

Genetic identity of cellular receptor for the immune system's first-response antibody discovered

Researchers at the University of Alabama at Birmingham (UAB) have uncovered the genetic identity of a cellular receptor for the immune system's first-response antibody, a discovery that sheds new light on infection control and immune disorders. The discovery is such a crucial part of immunology that UAB researchers, in conjunction with Japanese researchers, are asking that the gene linked to this antibody receptor be renamed to better describe its role in early immune responses.

19 Nov 2009

Why avian flu virus has not caused a pandemic?

Bird flu viruses would have to make at least two simultaneous genetic mutations before they could be transmitted readily from human to human, according to research published today in PLoS ONE.

19 Nov 2009

Possible new approach to slow the progression of cognitive decline in Down's syndrome

A study by neuroscientist William C. Mobley, MD, PhD, chair of the Department of Neurosciences at the University of California, San Diego School of Medicine, and colleagues at Stanford University Medical School has demonstrated a possible new approach to slowing the inevitable progression of cognitive decline found in Down's syndrome.

19 Nov 2009

Toddlers and obese children suffer more than youth when exposed to secondhand smoke

Toddlers and obese children suffer more than other youth when exposed to secondhand smoke, according to research presented at the American Heart Association's Scientific Sessions 2009.

19 Nov 2009

BIMR wins a GO grant from the National Institute of Mental Health

Thanks to a $50,000 grant from the California Bipolar Foundation (CBF) to post-doctoral research fellow Dr. Illyas Singec at the Burnham Institute for Medical Research (BIMR), a research team headed by Dr. Evan Snyder (along with co-investigators Drs. Dieter Wolfe and Lawrence Brill), was able to accumulate sufficient preliminary data to win an extremely competitive Grand Opportunities (GO) grant from the National Institute of Mental Health to explore the molecular basis of Bipolar Disorder (BPD).

19 Nov 2009

New biomarkers can predict patients' response to certain drugs

Recent advances in cancer therapeutics have led to the discovery of biomarkers that can predict patient response to certain drugs. Screening for mutations in the epidermal growth factor receptor (EGRF) prior to non-small cell lung cancer treatment, for example, has been shown to indentify patients who are likely to respond to treatment with erlontinib. This maximizes the drug's impact, and spares patients who are not likely to benefit from being subjected to potentially debilitating side effects.

19 Nov 2009

instaCare reports third quarter 2009 financial results

instaCare Corp., (OTC Bulletin Board: ISCR), a leading distributor of life-saving prescription drugs and at-home testing diagnostics for the chronically ill, and a leading developer of patentable technologies for e-pharmacy, e-health and EMR applications, reported financial results for the third quarter period-ended September 30, 2009.

19 Nov 2009

Study: EP4 agonist may reduce gastric bleeding and inflammation

Over 300 million patients use non-steroidal anti-inflammatory drugs (NSAIDs) in the world to treat pain, arthritis, fever and other diseases. Nearly 30% of the users suffer from gastric lesions and bleeding.

19 Nov 2009

Data from Phase 1 safety study of SB-728-T announced

Sangamo BioSciences, Inc. announced today that data from the University of Pennsylvania investigator sponsored Phase 1 safety study of Sangamo's zinc finger nuclease (ZFN) based product, SB-728-T, for HIV/AIDS were inadvertently and prematurely disclosed on the internet.

19 Nov 2009

FDA issues complete response for Rituxan, a drug for treating chronic lymphocytic leukemia

Genentech, Inc., a wholly-owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), and Biogen Idec announced today that the U.S. Food and Drug Administration (FDA) issued a complete response on the companies’ applications for Rituxan® (rituximab) plus fludarabine and cyclophosphamide (FC) for the treatment of people with previously untreated and previously treated chronic lymphocytic leukemia (CLL).

19 Nov 2009

Queen’s University Belfast to study individualized radiotherapy treatment for breast cancer

Individualised radiotherapy treatment based on a person’s genetic make up could soon become a reality, according to Breast Cancer Campaign.

19 Nov 2009

Researchers develop new device with nano-sized features to grab cancer cells

Just as fly paper captures insects, an innovative new device with nano-sized features developed by researchers at UCLA is able to grab cancer cells in the blood that have broken off from a tumor.

19 Nov 2009

Pfizer and DNDi to battle against HAT, VL and Chagas disease

Pfizer Inc and Drugs for Neglected Diseases initiative (DNDi) have signed an agreement that is designed to facilitate advancements in the battle against human African trypanosomiasis (HAT), visceral leishmaniasis (VL) and Chagas disease, which afflict vulnerable populations in the developing world.

19 Nov 2009

Cell News and Research

Aegera Therapeutics commences AEG35156 Phase 2B study for AML

WaferGen Biosystems launches new SmartChip Service for gene-expression profiling of thousands of genes

ISCO, Scripps Research Institute collaborate in study of parthenogenetic stem cells

Interim data from Geron's ongoing imetelstat trial presented at the AACR-NCI-EORTC conference

Exaggerated responses of immune system explain elders’ susceptibility to viral infections

Brain uses a mechanism to filter out distracting thoughts to focus on single information

NanoString Technologies to investigate molecular networks with the Broad Institute of MIT and Harvard

Genetic identity of cellular receptor for the immune system's first-response antibody discovered

Why avian flu virus has not caused a pandemic?

Possible new approach to slow the progression of cognitive decline in Down's syndrome

Toddlers and obese children suffer more than youth when exposed to secondhand smoke

BIMR wins a GO grant from the National Institute of Mental Health

New biomarkers can predict patients' response to certain drugs

instaCare reports third quarter 2009 financial results

Study: EP4 agonist may reduce gastric bleeding and inflammation

Data from Phase 1 safety study of SB-728-T announced

FDA issues complete response for Rituxan, a drug for treating chronic lymphocytic leukemia

Queen’s University Belfast to study individualized radiotherapy treatment for breast cancer

Researchers develop new device with nano-sized features to grab cancer cells

Pfizer and DNDi to battle against HAT, VL and Chagas disease

How to optimize your cell line development eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo